CO4980849A1 - Composiciones farmaceuticas -2-hidroximetil-1,3-oxatiolan-5-il)-(1h)-pirimidin-2-ona(la mivudina), y su uso en terapia medica - Google Patents
Composiciones farmaceuticas -2-hidroximetil-1,3-oxatiolan-5-il)-(1h)-pirimidin-2-ona(la mivudina), y su uso en terapia medicaInfo
- Publication number
- CO4980849A1 CO4980849A1 CO98015975A CO98015975A CO4980849A1 CO 4980849 A1 CO4980849 A1 CO 4980849A1 CO 98015975 A CO98015975 A CO 98015975A CO 98015975 A CO98015975 A CO 98015975A CO 4980849 A1 CO4980849 A1 CO 4980849A1
- Authority
- CO
- Colombia
- Prior art keywords
- concentrations
- mivudina
- oxatiolan
- hidroximetil
- pirimidin
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 238000013160 medical therapy Methods 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 abstract 2
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 abstract 2
- 229960001627 lamivudine Drugs 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 244000005700 microbiome Species 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- AIDS & HIV (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una composición farmacéutica, substancialmente libre de etanol yácido etilendiaminotetraacético, caracterizada porque comprende lamivudina o un derivado farmacéuticamente aceptable de la misma, y un sistema conservador. Una composición farmacéutica, caracterizada porque comprende lamivudina, la formulación que está substancialmente libre de etanol y ácido etilendiaminatetraacético y que cumple las siguientes especificaciones: (a). Las concentraciones de las bacterias viables se reducen a no más de 0,1% de las concentraciones iniciales por el décimo cuarto día; (b). Las concentraciones de las levaduras viables y mohos permanecen en, o bajo las concentraciones iniciales durante los primeros catorce días; y (c). Las concentraciones de cada uno de los microorganismos de prueba permanecen en, o abajo de esos niveles designados durante el resto del período de prueba de 28 días.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4235397P | 1997-03-24 | 1997-03-24 | |
| GBGB9706295.4A GB9706295D0 (en) | 1997-03-26 | 1997-03-26 | Lamivudine formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO4980849A1 true CO4980849A1 (es) | 2000-11-27 |
Family
ID=26311267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO98015975A CO4980849A1 (es) | 1997-03-24 | 1998-03-20 | Composiciones farmaceuticas -2-hidroximetil-1,3-oxatiolan-5-il)-(1h)-pirimidin-2-ona(la mivudina), y su uso en terapia medica |
Country Status (40)
| Country | Link |
|---|---|
| US (1) | US6004968A (es) |
| EP (1) | EP0969815B1 (es) |
| JP (1) | JP3264937B2 (es) |
| KR (1) | KR100484695B1 (es) |
| CN (1) | CN1191061C (es) |
| AP (1) | AP1141A (es) |
| AR (1) | AR011697A1 (es) |
| AT (1) | ATE295150T1 (es) |
| AU (1) | AU728461B2 (es) |
| BG (1) | BG64690B1 (es) |
| BR (1) | BR9808060B1 (es) |
| CA (1) | CA2286126C (es) |
| CO (1) | CO4980849A1 (es) |
| CY (1) | CY2569B1 (es) |
| CZ (1) | CZ298008B6 (es) |
| DE (1) | DE69830154T2 (es) |
| EA (1) | EA001990B1 (es) |
| EE (1) | EE03996B1 (es) |
| ES (1) | ES2239802T3 (es) |
| HK (1) | HK1022853A1 (es) |
| HN (1) | HN1998000045A (es) |
| HR (1) | HRP980154B1 (es) |
| HU (1) | HU225600B1 (es) |
| ID (1) | ID29294A (es) |
| IL (1) | IL131917A0 (es) |
| IS (1) | IS2515B (es) |
| MY (1) | MY116242A (es) |
| NO (1) | NO326719B1 (es) |
| NZ (1) | NZ337798A (es) |
| PA (1) | PA8449301A1 (es) |
| PE (1) | PE61699A1 (es) |
| PL (1) | PL190505B1 (es) |
| PT (1) | PT969815E (es) |
| RS (1) | RS49772B (es) |
| SI (1) | SI0969815T1 (es) |
| SK (1) | SK283417B6 (es) |
| SV (1) | SV1998000040A (es) |
| TW (1) | TW536403B (es) |
| UY (1) | UY24930A1 (es) |
| WO (1) | WO1998042321A2 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69727240T2 (de) | 1996-06-25 | 2004-11-25 | Glaxo Group Ltd., Greenford | Kombinationen, enthaltend VX478, Zidovudin und 3TC zur Behandlung von HIV |
| US6018044A (en) * | 1998-01-02 | 2000-01-25 | Roche Vitamins Inc. | Light screening compositions |
| US6432966B2 (en) * | 1999-10-29 | 2002-08-13 | Smithkline Beecham Corporation | Antiviral combinations |
| JP2003039582A (ja) * | 2001-07-19 | 2003-02-13 | Three M Innovative Properties Co | 湿潤防滑性シート及び湿潤防滑構造体 |
| US6855346B2 (en) * | 2001-10-05 | 2005-02-15 | Tzu-Sheng Wu | Pharmaceutical composition having prophylactic effects on lamivudine-related disease relapse and drug resistance and methods of using the same |
| MY131488A (en) * | 2002-04-08 | 2007-08-30 | Bristol Myers Squibb Co | Low dose liquid entecavir formulations and use |
| CA2517310C (en) | 2003-02-28 | 2015-11-24 | Chugai Seiyaku Kabushiki Kaisha | Stabilized protein-containing formulations comprising a poloxamer |
| US20040228804A1 (en) * | 2003-05-16 | 2004-11-18 | Jones Alonzo H. | Nasal administration of xylitol to a non-human mammal |
| PE20060484A1 (es) * | 2004-07-14 | 2006-07-06 | Ucb Farchim Sa | Preparaciones farmaceuticas liquidas que comprenden un compuesto de benzhidril piperizina |
| CN100427082C (zh) * | 2005-08-02 | 2008-10-22 | 盛华（广州）医药科技有限公司 | 羟基苯甲酸酯及其类似物在制备预防和治疗病毒性感染药物中的应用 |
| GB2470494B (en) * | 2008-01-17 | 2012-08-08 | Univ Holy Ghost Duquesne | Antiretroviral drug formulations for treatment of children exposed to HIV/AIDS |
| RU2587782C1 (ru) * | 2015-01-19 | 2016-06-20 | Общество с ограниченной ответственностью "Трейдсервис" | Стабильная фармацевтическая композиция ламивудина |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5047407A (en) * | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
| DE19875016I2 (de) * | 1991-05-16 | 2004-07-01 | Glaxo Group Ltd | Nukleosidanalogen enthaltende Antiviren-Zubereitungen. |
| GB9111902D0 (en) * | 1991-06-03 | 1991-07-24 | Glaxo Group Ltd | Chemical compounds |
| GB9503850D0 (en) * | 1995-02-25 | 1995-04-19 | Glaxo Group Ltd | Medicaments |
| MY115461A (en) * | 1995-03-30 | 2003-06-30 | Wellcome Found | Synergistic combinations of zidovudine, 1592u89 and 3tc |
| GB9605293D0 (en) * | 1996-03-13 | 1996-05-15 | Glaxo Group Ltd | Medicaments |
-
1998
- 1998-03-16 TW TW087103841A patent/TW536403B/zh not_active IP Right Cessation
- 1998-03-20 PE PE1998000203A patent/PE61699A1/es not_active IP Right Cessation
- 1998-03-20 KR KR10-1999-7008690A patent/KR100484695B1/ko not_active IP Right Cessation
- 1998-03-20 EA EA199900757A patent/EA001990B1/ru not_active IP Right Cessation
- 1998-03-20 NZ NZ337798A patent/NZ337798A/xx not_active IP Right Cessation
- 1998-03-20 RS YUP-477/99A patent/RS49772B/sr unknown
- 1998-03-20 CN CNB988051222A patent/CN1191061C/zh not_active Expired - Lifetime
- 1998-03-20 IL IL13191798A patent/IL131917A0/xx not_active IP Right Cessation
- 1998-03-20 DE DE69830154T patent/DE69830154T2/de not_active Expired - Lifetime
- 1998-03-20 WO PCT/EP1998/001626 patent/WO1998042321A2/en active IP Right Grant
- 1998-03-20 AT AT98919120T patent/ATE295150T1/de active
- 1998-03-20 HU HU0002982A patent/HU225600B1/hu unknown
- 1998-03-20 CO CO98015975A patent/CO4980849A1/es unknown
- 1998-03-20 US US09/044,896 patent/US6004968A/en not_active Expired - Lifetime
- 1998-03-20 MY MYPI98001227A patent/MY116242A/en unknown
- 1998-03-20 SI SI9830767T patent/SI0969815T1/xx unknown
- 1998-03-20 SV SV1998000040A patent/SV1998000040A/es active IP Right Grant
- 1998-03-20 CZ CZ0340399A patent/CZ298008B6/cs not_active IP Right Cessation
- 1998-03-20 EE EEP199900440A patent/EE03996B1/xx unknown
- 1998-03-20 PT PT98919120T patent/PT969815E/pt unknown
- 1998-03-20 JP JP54442598A patent/JP3264937B2/ja not_active Expired - Lifetime
- 1998-03-20 PA PA19988449301A patent/PA8449301A1/es unknown
- 1998-03-20 CA CA002286126A patent/CA2286126C/en not_active Expired - Lifetime
- 1998-03-20 SK SK1299-99A patent/SK283417B6/sk not_active IP Right Cessation
- 1998-03-20 HN HN1998000045A patent/HN1998000045A/es unknown
- 1998-03-20 PL PL98336038A patent/PL190505B1/pl unknown
- 1998-03-20 EP EP98919120A patent/EP0969815B1/en not_active Expired - Lifetime
- 1998-03-20 AU AU72084/98A patent/AU728461B2/en not_active Expired
- 1998-03-20 ID IDW991096A patent/ID29294A/id unknown
- 1998-03-20 AP APAP/P/1999/001657A patent/AP1141A/en active
- 1998-03-20 BR BRPI9808060-1A patent/BR9808060B1/pt not_active IP Right Cessation
- 1998-03-20 ES ES98919120T patent/ES2239802T3/es not_active Expired - Lifetime
- 1998-03-23 HR HR980154A patent/HRP980154B1/xx not_active IP Right Cessation
- 1998-03-23 AR ARP980101317A patent/AR011697A1/es active IP Right Grant
- 1998-03-23 UY UY24930A patent/UY24930A1/es not_active IP Right Cessation
-
1999
- 1999-09-17 IS IS5184A patent/IS2515B/is unknown
- 1999-09-23 NO NO994619A patent/NO326719B1/no not_active IP Right Cessation
- 1999-10-18 BG BG103818A patent/BG64690B1/bg unknown
-
2000
- 2000-04-07 HK HK00102154A patent/HK1022853A1/xx not_active IP Right Cessation
-
2006
- 2006-11-09 CY CY0600032A patent/CY2569B1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI872864A0 (fi) | Menetelmä farmaseuttisesti aktiivisten bentsimidatsolijohdannaisten valmistamiseksi | |
| SE8804629D0 (sv) | New therapeutically active compounds | |
| HUP0101999A2 (hu) | 4-Hidroxi-kinolin-3-karboxamid- és -hidrazid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása | |
| NO166448C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive tiazolidindioner. | |
| NO973059L (no) | Hydroksylaminderivater som er anvendbare for å öke den molekylære chaperonproduksjon, og fremstilling derav | |
| ES2082755T3 (es) | Derivados de acido 3-desmetil-mevalonico, procedimiento para su preparacion, preparados farmaceuticos a base de estos compuestos, su utilizacion asi como productos intermedios. | |
| CO4980849A1 (es) | Composiciones farmaceuticas -2-hidroximetil-1,3-oxatiolan-5-il)-(1h)-pirimidin-2-ona(la mivudina), y su uso en terapia medica | |
| DK499088D0 (da) | 1-oe(2-pyrimidinyl)-aminoalkylaapiperidinderivater, fremgangsmaade til fremstilling deraf og laegemiddel indeholdende saadanne derivater | |
| ATE38991T1 (de) | In 2-stellung substituierte 1,3propyledendephosphonat-derivate, ihre herstellung und pharmazeutische zusammensetzungen, die sie enthalten. | |
| MX9204637A (es) | Nuevos derivados de pirazina y procedimiento para su preparacion. | |
| BR0012610A (pt) | Novo derivado de difenilpiperidina | |
| HUP9802861A2 (hu) | Calendula glikozidok alkalmazása bőrsejtek túlburjánzásával kapcsolatos betegségek, így psoriasis kezelésére alkalmas gyógyászati készítmény előállítására, ezen vegyületek, valamint ezeket tartalmazó gyógyászati készítmények | |
| DK359387A (da) | Oploesninger af oxazaphosphoriner med forbedret stabilitet og fremgangsmaade til deres fremstilling | |
| ATE2265T1 (de) | Sekundaere amine, ihre herstellung und verwendung in pharmazeutischen zusammensetzungen. | |
| FI854179L (fi) | Antibakterieblandning och framstaellningsfoerfarande foer dess aktiva aemnen. | |
| ATE13765T1 (de) | 2-(1,4-benzodioxan-2-ylalkyl)-imidazole, deren herstellung und sie enthaltende pharmazeutische mittel. | |
| DE3764111D1 (de) | Arzneimittelkombination. | |
| DK469687A (da) | Derivater af 4,5-dihydrooxazoler og fremgangsmaade til fremstilling af saadanne derivater. | |
| DK154385D0 (da) | Tetrahydrothienopyridiner eller farmaceutisk uskadelige salte deraf, deres fremstilling og anvendelse som laegemidler | |
| AU658175B2 (en) | Use of 2-iminothiazolidin-4-one derivatives as novel pharmaceutical active ingredients | |
| SE8004383L (sv) | Farmaceutisk beredning for oral administrering och forfarande for dess framstellning | |
| DK313587D0 (da) | Tetrahydrobenzothiazolforbindelser, deres fremstilling og anvendelse | |
| ES2160117T3 (es) | Composicion farmaceutica antitumoral a base de carboplatino, y su procedimiento de produccion. | |
| FI860098A0 (fi) | Nya piperazinderivat, foerfarande foer deras framstaellning och farmaceutiska kompositioner som innehaoller dessa foereningar som aktiv ingrediens. | |
| DK364386A (da) | 1-alkyl-ergolinyl-thiourinstofderivater og fremgangsmaade til fremstilling deraf samt deres anvendelse |